{"title":"探讨肝脏的生理、病理、TGF-β、EMT、干细胞和肝癌的新进展。","authors":"Isabel Fabregat","doi":"10.2217/hep-2017-0007","DOIUrl":null,"url":null,"abstract":"<p><p><b>Isabel Fabregat speaks to Roshaine Wijayatunga, Managing Commissioning Editor.</b> Isabel Fabregat, PhD, is Senior Investigator, Head of the group \"TGF-β and cancer\", at the Bellvitge Biomedical Research Institute (IDIBELL) and Associate Professor in the School of Medicine and Health Sciences at the University of Barcelona. She is the President of the Spanish Society for Cell Biology since 2011, she was member of the Executive Board of the Spanish Branch of the European Tissue Culture Society and she is currently member of the Spanish Society for the Study of the Liver, and the International Liver Cancer Association, among others. The current research line of her laboratory focuses on the dissection of the molecular mechanisms induced by TGF-β in liver cells that can explain its different, and sometimes opposite, functions in liver pathologies, in particular fibrosis and hepatocarcinogenesis. Cross-talk between TGF-β and other pathways, in particular EGFR signaling, is also one of the current interests of the lab. From October 2012 she has coordinated an Initial Training Network - Marie Curie European Action that under the acronym of 'IT-LIVER' (Inhibiting TGF-β in Liver Diseases) integrates different European academic groups and small enterprises to develop a multidisciplinary training program for talented young researchers, to prepare them for leading roles in chronic liver disease research. Dr Fabregat has published around 130 articles in indexed journals, as well as several book chapters, with her work published in <i>Hepatology</i>, <i>Journal of Hepatology</i>, <i>Genes & Development</i>, <i>Cancer Research</i>, <i>Oncogene</i>, <i>FASEB Journal</i>, <i>Free Radical in Biology & Medicine</i>, <i>Journal of Cell Science</i>, <i>Journal of Biological Chemistry</i>, among others. She is an editorial member of the <i>World Journal of Gastroenterology</i>, <i>World Journal of Hepatology</i>, <i>Frontiers in Physiology-Gastrointestinal Sciences</i>, <i>Frontiers in Pharmacology</i>, <i>Current Signal Transduction Therapy</i> and <i>Hepatic Oncology</i>.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"4 1","pages":"9-13"},"PeriodicalIF":1.2000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2017-0007","citationCount":"5","resultStr":"{\"title\":\"Exploring liver physiology, pathology, TGF-β, EMT, stemness and new developments in liver cancer.\",\"authors\":\"Isabel Fabregat\",\"doi\":\"10.2217/hep-2017-0007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Isabel Fabregat speaks to Roshaine Wijayatunga, Managing Commissioning Editor.</b> Isabel Fabregat, PhD, is Senior Investigator, Head of the group \\\"TGF-β and cancer\\\", at the Bellvitge Biomedical Research Institute (IDIBELL) and Associate Professor in the School of Medicine and Health Sciences at the University of Barcelona. She is the President of the Spanish Society for Cell Biology since 2011, she was member of the Executive Board of the Spanish Branch of the European Tissue Culture Society and she is currently member of the Spanish Society for the Study of the Liver, and the International Liver Cancer Association, among others. The current research line of her laboratory focuses on the dissection of the molecular mechanisms induced by TGF-β in liver cells that can explain its different, and sometimes opposite, functions in liver pathologies, in particular fibrosis and hepatocarcinogenesis. Cross-talk between TGF-β and other pathways, in particular EGFR signaling, is also one of the current interests of the lab. From October 2012 she has coordinated an Initial Training Network - Marie Curie European Action that under the acronym of 'IT-LIVER' (Inhibiting TGF-β in Liver Diseases) integrates different European academic groups and small enterprises to develop a multidisciplinary training program for talented young researchers, to prepare them for leading roles in chronic liver disease research. Dr Fabregat has published around 130 articles in indexed journals, as well as several book chapters, with her work published in <i>Hepatology</i>, <i>Journal of Hepatology</i>, <i>Genes & Development</i>, <i>Cancer Research</i>, <i>Oncogene</i>, <i>FASEB Journal</i>, <i>Free Radical in Biology & Medicine</i>, <i>Journal of Cell Science</i>, <i>Journal of Biological Chemistry</i>, among others. She is an editorial member of the <i>World Journal of Gastroenterology</i>, <i>World Journal of Hepatology</i>, <i>Frontiers in Physiology-Gastrointestinal Sciences</i>, <i>Frontiers in Pharmacology</i>, <i>Current Signal Transduction Therapy</i> and <i>Hepatic Oncology</i>.</p>\",\"PeriodicalId\":44854,\"journal\":{\"name\":\"Hepatic Oncology\",\"volume\":\"4 1\",\"pages\":\"9-13\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2017-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/hep-2017-0007\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hepatic Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/hep-2017-0007\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2017/7/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/hep-2017-0007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/7/6 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Exploring liver physiology, pathology, TGF-β, EMT, stemness and new developments in liver cancer.
Isabel Fabregat speaks to Roshaine Wijayatunga, Managing Commissioning Editor. Isabel Fabregat, PhD, is Senior Investigator, Head of the group "TGF-β and cancer", at the Bellvitge Biomedical Research Institute (IDIBELL) and Associate Professor in the School of Medicine and Health Sciences at the University of Barcelona. She is the President of the Spanish Society for Cell Biology since 2011, she was member of the Executive Board of the Spanish Branch of the European Tissue Culture Society and she is currently member of the Spanish Society for the Study of the Liver, and the International Liver Cancer Association, among others. The current research line of her laboratory focuses on the dissection of the molecular mechanisms induced by TGF-β in liver cells that can explain its different, and sometimes opposite, functions in liver pathologies, in particular fibrosis and hepatocarcinogenesis. Cross-talk between TGF-β and other pathways, in particular EGFR signaling, is also one of the current interests of the lab. From October 2012 she has coordinated an Initial Training Network - Marie Curie European Action that under the acronym of 'IT-LIVER' (Inhibiting TGF-β in Liver Diseases) integrates different European academic groups and small enterprises to develop a multidisciplinary training program for talented young researchers, to prepare them for leading roles in chronic liver disease research. Dr Fabregat has published around 130 articles in indexed journals, as well as several book chapters, with her work published in Hepatology, Journal of Hepatology, Genes & Development, Cancer Research, Oncogene, FASEB Journal, Free Radical in Biology & Medicine, Journal of Cell Science, Journal of Biological Chemistry, among others. She is an editorial member of the World Journal of Gastroenterology, World Journal of Hepatology, Frontiers in Physiology-Gastrointestinal Sciences, Frontiers in Pharmacology, Current Signal Transduction Therapy and Hepatic Oncology.
期刊介绍：
Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
